Inspections, Compliance, Enforcement, and Criminal Investigations
Radiological Associates of Sacramento Medical Group, Inc. 05-09-01 DETAIL
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
San Francisco District
1431 Harbor Bay Parkway
Alameda, CA 94502-7070
September 5, 2001
Via Federal Express
MQSA Facility ID: 148932
Inspection ID: 1489320007
Nancy Reed, Director of Operations
Radiological Associates Of Sacramento Medical Group, Inc.
2 Scripps Drive Suite 110
Sacramento, CA 95825
Dear Nancy Reed:
We are writing to you because on August 16, 2001, your facility was inspected by a
representative of the State of California, acting in behalf of the Food and Drug
Administration (FDA). This inspection revealed a serious regulatory problem involving
the mammography at your facility.
Under a Limited States Federal law, the mammography Quality Standards Act of 1992,
your facility must meet specific requirements for mammography. These requirements
help protect the health of women by assuring that a facility can perform quality
mammography. The inspection revealed the following level 1 finding at your facility
Level 1: Phantom QC records were missing for at least 4 weeks for unit 4, [redacted]
Room [redacted] ROOM
The specific problem noted above appeared on your MQSA Facility Inspection Report
which was issued to your facility at the close of the inspection. This problem is identified
as Level 1, because it identifies a failure to meet a significant MQSA requirement.
Because this condition may be symptomatic of serious underlying problems that could
compromise the quality of mammography at your facility, it represents a serious violation
of the law which may result in FDA taking regulatory action without further notice to
you. These actions include, but are not limited to, placing your facility under a Directed
Plan of Correction, charging your facility for the cost of on-site monitoring, assessing
civil money penalties up to $10,000 for each failure to substantially comply with, or each
day of failure to substantially comply with, MQSA Standards, suspension or revocation
of your facility?s FDA certificate, or obtaining a court injunction against further
We acknowledge receipt of Jan Curry?s, Site Supervisor, letter dated August 23, 2001
responding to the Level 1 finding discussed above. Ms. Curry?s response appears to
adequately address the Level 1 finding. Your corrective actions will be verified during
the next inspection.
Finally, you should understand that there are many FDA requirements pertaining to
mammography. This letter pertains only to findings of your inspection and does not
necessarily address other obligations you have under the law. You may obtain general
information about all of FDA?s requirements for mammography facilities by contacting
the Mammography Quality Assurance Program, Food and Drug Administration, P.O.
Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet athttp://www.fda.gov.
If you have more specific questions about mammography facility requirements, or about
the content of this letter, please feel free to contact Russell A. Campbell, Compliance Officer, at 510-337-6861.
Dennis K. Linsley